Results 141 to 150 of about 2,254 (197)
Current Medical Research and Opinion, 2004 Purpose: To compare the efficacy and safety of the concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily with those of a fixed combination of latanoprost 0.005%/timolol 0.5% once daily. Research, design and methods:
Julian Garcia-Feijoo +2 more
exaly +2 more sources
Quantitation of brinzolamide in dried blood spots by a novel LC-QTOF-MS/MS method
Journal of Pharmaceutical and Biomedical Analysis, 2016 In the current study, a rapid and sensitive LC-QTOF-MS/MS method for the determination of brinzolamide in dried blood spots (DBS) was developed and validated.
Anđelija Malenović +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy, 2008
Primary open-angle glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. However, the primary risk factor is elevated intraocular pressure (IOP), which can damage the optic nerve head (ONH) and until now was the only treatable risk factor.
openaire +3 more sources
Primary open-angle glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. However, the primary risk factor is elevated intraocular pressure (IOP), which can damage the optic nerve head (ONH) and until now was the only treatable risk factor.
openaire +3 more sources
Short-Term Effect of Topical Brinzolamide on Human Central Corneal Thickness
European Journal of Ophthalmology, 2008 PURPOSE. To investigate the effect of short-term brinzolamide application on human central corneal thickness (CCT). METHODS. Seventeen eyes of 16 patients who underwent neodymium: YAG laser posterior capsulotomy were included in the study group.
K Örnek
exaly +2 more sources
Preclinical Overview of Brinzolamide
Survey of Ophthalmology, 2000The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which is involved in aqueous humor secretion.
openaire +2 more sources
Drugs & Aging, 2009
Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the beta-adrenergic receptor antagonist timolol. Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective ...
Jamie D, Croxtall, Lesley J, Scott
openaire +2 more sources
Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the beta-adrenergic receptor antagonist timolol. Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective ...
Jamie D, Croxtall, Lesley J, Scott
openaire +2 more sources
Topical brinzolamide for foveal schisis in juvenile retinoschisis
Journal of American Association for Pediatric Ophthalmology and Strabismus, 2013We describe a case series of 4 consecutive patients diagnosed with X-linked retinoschisis seen at a pediatric ophthalmology clinic during a 3-year period. All patients were treated with topical brinzolamide; 3 patients experienced significantly decreased severity of macular cysts on OCT in at least one eye.
Francine P, Yang +2 more
openaire +2 more sources